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Comparative effectiveness of secukinumab and etanercept 
in biologic-naïve patients with psoriatic arthritis assessed 
by matching-adjusted indirect comparison
Introduction
Active psoriatic arthritis (PsA) is typically treated with conventional synthetic biologic disease-modifying 
anti-rheumatic drugs (csDMARDs) as first systemic treatment (1). Both the European League against Rheu-
matism (1, 2) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) (3) 
recommend the use of biologic DMARDs (bDMARDs) when response to csDMARDs is inadequate. The 
GRAPPA guidelines also recommend biologic therapy, if feasible, in patients with evidence of aggressive 
disease progression. Currently approved and recommended bDMARDs comprise the tumor necrosis factor 
inhibitors (TNFis) adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab, and the mono-
clonal antibodies ustekinumab, which targets interleukin (IL)-12/23, and secukinumab and ixekizumab, 
which target IL-17A. The targeted synthetic DMARD apremilast, a small-molecule inhibitor that modulates 
inflammatory cytokine production via the inhibition of phosphodiesterase 4, has also been approved for 
the treatment of PsA.
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Abstract
Objective: Matching-adjusted indirect comparison (MAIC) can be used to assess the comparative 
effectiveness of two treatments indirectly using data from randomized placebo-controlled trials. 
This MAIC assessed the comparative effectiveness of secukinumab (an anti-interleukin-17A) and 
etanercept (a tumor necrosis factor inhibitor) in a target population of biologic-naïve patients with 
psoriatic arthritis (PsA).
Methods: Individual patient data pooled from FUTURE 2 (NCT01752634), FUTURE 3 (NCT01989468), 
and FUTURE 5 (NCT02404350) (secukinumab: 150 mg, n=458 and 300 mg, n=461) were matched 
to data from the population in the NCT00317499 trial (etanercept 25 mg, n=101) using MAIC 
meth odology, by adjusting for clinical and demographic baseline characteristics. Recalculated 
outcomes from FUTURE 2, 3, and 5 (150 mg, effective sample size (ESS) post-matching=104; 
300 mg, ESS=75; and placebo, ESS=159) were compared with the NCT00317499 trial. Pairwise 
comparisons using odds ratios (ORs) were performed for the American College of Rheumatology 
(ACR) 20, 50, and 70 response criteria at week 12 (placebo-adjusted) and week 24 (non-place-
bo-adjusted).
Results: At week 12, there were no significant differences in ACR responses between secukinumab 
and etanercept. There was no significant difference between secukinumab 150 mg and etanercept 
at week 24 with respect to ACR 20 and 50 response rates; however, ACR 70 response rates were 
higher for secukinumab 150 mg (OR (95% confidence interval (CI)): 4.48 (2.01–9.99), p<0.001). ACR 
20, 50, and 70 response rates were higher with secukinumab 300 mg than with etanercept at this 
time point (OR (95% CI): ACR 20, 3.28 (1.69–6.38), p<0.001; ACR 50, 1.90 (1.04–3.50), p=0.038; and 
ACR 70, 3.56 (1.51–8.40), p=0.004).
Conclusion: In this MAIC, secukinumab was associated with higher ACR 20 and 50 (secukinumab 
300 mg) and 70 (secukinumab 150 mg and 300 mg) response rates at week 24 than etanercept 
in biologic-naïve patients with active PsA, whereas no significant difference was observed in the 
short-term at week 12.
Keywords: Comparative effectiveness, etanercept, matching-adjusted indirect comparison, psoriat-
ic arthritis, secukinumab
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Matching-adjusted indirect comparison (MAIC) 
is a statistical technique that simulates a direct 
comparison of two therapies (4, 5) by match-
ing individual patient data (IPD) from one trial 
to published aggregate data from another trial 
(6, 7). MAIC is one of several methods that can 
be used to conduct indirect treatment com-
parisons when patient-level data are not avail-
able for all trials (8). When no head-to-head 
randomized controlled trials (RCTs) have been 
conducted, such methods may generate the 
best RCT-based comparative evidence avail-
able.
Health technology assessment agencies have 
acknowledged MAIC as a robust analysis 
method (9), and the UK’s National Institute for 
Health and Care Excellence (NICE) has pub-
lished methodological guidelines on its use (5, 
8). MAIC has been used to provide comparative 
effectiveness evidence in multiple therapeutic 
areas, including PsA (10-12).
In the present study, secukinumab, a fully 
human IL-17A inhibitor, with etanercept, a re-
combinant TNF receptor–immunoglobulin G 
fusion protein, was compared using pooled 
IPD from the FUTURE 2 (NCT01752634) (13), 
FUTURE 3 (NCT01989468) (14), and FUTURE 5 
(NCT02404350) (15) trials for secukinumab and 
aggregate data from the NCT00317499 trial for 
etanercept (16) in a target population of bio-
logic-naïve patients with PsA.
Methods 
MAIC
The MAIC methodology comprises four main 
steps and has been described in detail in previ-
ous studies (5, 11).
Identification of source data by systematic litera-
ture review (SLR)
The SLR conducted to identify evidence is sum-
marized in the Supplementary Methods section.
Studies included
FUTURE 2 (13), FUTURE 3 (14), FUTURE 5 (15), 
and NCT00317499 (16) were large, random-
ized, double-blind, placebo-controlled phase 
3 studies (Figure 1) with the primary endpoint 
of proportion of patients achieving a ≥20% 
improvement in the American College of 
Rheumatology (ACR) response criteria (ACR 
20) (17) at week 24 (FUTURE 2, FUTURE 3, and 
NCT00317499) or week 16 (FUTURE 5).
The FUTURE 2, 3, and 5 trials were similar with 
respect to inclusion/exclusion criteria, follow-up 
period, and setting, and included the approved 
150 mg and 300 mg doses of secukinumab, 
which allowed us to pool IPD across the three 
trials, increasing the potential effective sam-
ple size (ESS) following matching. Patients in 
NCT00317499 received etanercept 25 mg twice 
weekly. This is an approved dosing strategy 
according to the European Medicines Agency 
recommendation; however, the US Food and 
Drug Administration recommends 50 mg once 
weekly.
Patients who had previously experienced fail-
ure of TNFi therapy up to three times were 
eligible for inclusion in FUTURE 2, 3, and 
5, whereas all patients were TNFi-naïve in 
NCT00317499.
Selection of baseline characteristics for matching 
study populations
The choice of baseline characteristics for 
matching was based on clinical expert advice, 
targeted literature review, and statistical analy-
ses of effect modifiers, as described previously 
(18) and in line with the NICE guidelines (5).
Our principal analysis used 11 baseline charac-
teristics for matching, including most of the es-
tablished prognostic variables used in previous 
MAICs in PsA as matching parameters (12, 18). 
The number of patients with active concom-
itant psoriasis (≥3% body surface area) was 
used as a matching characteristic; however, 
Psoriasis Area and Severity Index (PASI) score at 
baseline could not be used because these data 
were not published for NCT00317499. PsA dis-
ease duration (time since diagnosis), swollen 
joint count, and C-reactive protein (CRP) levels 
at baseline were used in matching, but were 
omitted from the sensitivity analysis, which de-
creased the matching stringency but provided 
a larger ESS.
Rates of methotrexate use at baseline were 
higher for patients in the FUTURE 2, 3, and 5 
trials than for those in the NCT00317499 trial, 
and PsA duration, number of patients with 
psoriasis >3% of their body surface area, swol-
len joint count, and CRP levels were all lower, 
suggesting comparatively less severe disease 
in these patients (Table 1); this highlights the 
requirement for MAIC to avoid such potential 
confounding factors. Owing to these differenc-
es between populations, and the matching 
methodology, the target population for our 
analysis comprised patients similar to those in 
the NCT00317499 trial, with characteristics of 
severe disease, rather than biologic-naïve pa-
tients in general.
Matching and adjusting IPD to published aggre-
gate data
Pooled FUTURE 2, 3, and 5 IPD were weighted 
to match selected patient baseline characteris-
tics using published aggregate data from the 
etanercept arm of NCT00317499 (16). Placebo 
arms were also matched. This methodology 
was based on Signorovitch et al. (19), subse-
quent publications (4, 10, 20), and NICE guide-
lines (5).
The regression results were used to weigh pa-
tients in FUTURE 2, 3, and 5 so that each pa-
tient’s weight corresponded to their relative 
propensity for enrolling in FUTURE 2, 3, or 5 ver-
sus NCT00317499; following this, the weighted 
mean baseline characteristics of the pooled 
FUTURE 2, 3, and 5 populations matched those 
reported for NCT00317499, and the sample 
size of the pooled FUTURE 2, 3, and 5 data set 
was reduced to the ESS.
Comparing outcomes using recalculated patient data
After matching, the weights were used to re-
calculate outcomes for FUTURE 2, 3, and 5. 
These were aggregated and used to estimate 
the comparative effectiveness of secukinum-
ab and etanercept using published aggregate 
data from NCT00317499.
Analyses
Missing data reporting
All published outcomes included in this MAIC 
were from the intention-to-treat population. 
All missing ACR response data were derived 
using non-responder imputation. For 36-Item 
Short-Form Health Survey (SF-36) summary 
scores, missing values were imputed using the 
last observation carried forward (LOCF) meth-
od in the NCT00317499 trial; LOCF was also 
applied to analyze SF-36 data in FUTURE 2, 3, 
and 5 to ensure consistency in the definition of 
these outcome variables.
Outcomes
American College of Rheumatology 20, 50, 
and 70 response rates and SF-36 scores were 
selected for comparison, as recommended 
for PsA clinical trial data sets in the Outcomes 
Measures in Rheumatology (21, 22) and GRAP-
PA (23) guidelines. Outcomes were compared 
at weeks 12 and 24.
All trials measured health-related quality of 
life (HRQoL) at week 24 using the SF-36 and 
reported the physical component summary 
(PCS) and the mental component summary 
(MCS).
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Placebo-adjusted and non-placebo-adjusted out-
come comparisons
Our MAIC analyses were conducted using the 
Bucher method (7). Placebo-adjusted compari-
sons were possible at week 12, but not at week 
24; placebo arms were no longer comparable 
at this time point because patients could re-
ceive active treatment from week 16 in the FU-
TURE trials. Therefore, after week 12, outcomes 
from the etanercept arm of NCT00317499 
were compared with outcomes from the ad-
justed and recalculated pooled secukinumab 
150 mg and 300 mg arms of FUTURE 2, 3, and 5.
Pairwise comparisons
American College of Rheumatology out-
comes are reported as odds ratios (ORs) with 
95% confidence intervals (CIs) and p values. A 
standard p value threshold of ≤0.05 was used; 
furthermore, p values between 0.1 and 0.001 
were considered as “increasing evidence” and 
p≤0.001 as “strong evidence” against the null 
hypothesis (Supplementary Methods section).
Psoriasis Area and Severity Index outcomes were 
not reported in the present study because base-
line characteristic data for the NCT00317499 
psoriasis subgroup were not available, and 
therefore matching for this subgroup could not 
be performed appropriately.
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Table 1. Baseline characteristics before and after matching in the principal analysis
                         NCT00317499 trial                                 FUTURE 2/3/5 (before matching)                                FUTURE 2/3/5 (after matching) 
Baseline ETN 25 mg BIW PBO SEC 150 mg SEC 300 mg PBO SEC 150 mg SEC 300 mg PBO 
characteristics (n=101) (n=104) (n=458) (n=461) (n=567) (ESS=104) (ESS=75) (ESS=159)
Demographics
Age (years), mean* 47.6 47.3 48.5 (12.3) 48.6 (12.8) 49.4 (12.3) 47.6 (7.9) 47.6 (6.7) 47.3 (7.9)
Weight (kg), median* 88.4 88.4 85.0 82.5 82.3 88.5 88.7 88.0
Female, n (%) 43 (42.6) 57 (54.8) 231 (50.4) 235 (51.0) 308 (54.3) (42.6)† (42.6)† 54.8
   p=0.1525 p=0.1261  p=1.000 p=1.000
White, n (%) 91 (90) 95 (91) 397 (86.7) 410 (88.9) 501 (88.3) (90.0)† (90.0)† 91.0
   p=0.3505 p=0.7339  p=1.000 p=1.000
Disease characteristics
Methotrexate use 42 (42) 43 (41) 213 (46.5) 227 (49.2) 279 (49.2) (42.0)† (42.0)† 41.0
at baseline, n (%)   p=0.3686 p=0.1630  p=1.000 p=1.000
Psoriasis (≥3% BSA),
n (%) 66 (65.3) 62 (59.6) 251 (54.8) 213 (46.2) 264 (46.6) (65.3)† (65.3)† 59.6
   p=0.0529 p=0.0005  p=1.000 p=1.000
HAQ-DI at baseline, mean* 1.1 1.1 1.2 (0.6) 1.2 (0.6) 1.2 (0.6) 1.1 (0.4) 1.1 (0.4) 1.1 (0.4)
   p=0.1882 p=0.1876  p=1.000 p=1.000
PsA duration (years) 9 9.2 7.0 (7.8) 7.3 (8.4) 6.7 (7.4) 9.0 (7.3) 9.0 (5.9) 9.2 (6.6) 
   mean (SD)*
SJC, median* 13 12.5 9.0 8.0 8.0 13.0 13.0 13.0
CRP levels, median* 1.6 1.1 0.5 0.5 0.5 1.6 1.6 1.1
TNFi-naïve, n (%) 101 (100) 104 (100) 312 (68.1) 316 (68.5) 390 (68.8) (100.0)† (100.0)† 100.0
   p<0.0001 p<0.0001  p=1.000 p=1.000 
Variables not used for matching
TJC, median 18.0 17.0 16.0 15.0 16.0 19.0 17.0 18.0
SF-36 PCS, mean 35.8 35.7 36.9 (8.0) 37.7 (8.2) 36.7 (8.4) 38.0 (4.5) 38.9 (4.5) 38.2 (5.5)
SF-36 MCS, mean 50.9 48.4 41.8 (10.8) 44.1 (11.7) 43.7 (11.2) 42.6 (6.8) 43.7 (7.1) 45.4 (6.4)
Bold data indicate the post-matching baseline characteristics in each group
p values are for secukinumab compared with etanercept
*For continuous baseline characteristics in the NCT00317499 study, either only the median or  the mean without SD was reported. Therefore, in both cases, it was not possible to perform 
a statistical test
†Integer population (n) values were not available because pooled SEC ESS values were calculated using the equation
BIW: twice weekly; BSA: body surface area; CRP: C-reactive protein; ESS: effective sample size; ETN: etanercept; HAQ-DI: Health Assessment Questionnaire Disability Index; MCS: mental component 
summary; PBO: placebo; PCS: physical component summary; PsA: psoriatic arthritis; SD: standard deviation; SEC: secukinumab; SF-36: 36-Item Short-Form Health Survey; SJC: swollen joint count; 
TJC: tender joint count; TNFi: tumor necrosis factor inhibitor
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Figure 1. FUTURE 2, 3, and 5 and NCT00317499 trial designs
*Data from the secukinumab 75 mg arm of the FUTURE 2 study were not used in this MAIC. 
†Patients who had a ≥20% improvement compared with baseline in TJC and SJC. 
‡Patients who had a <20% improvement compared with baseline in TJC and SJC. 
§Patients who completed 12 weeks of the study drug in the 24-week placebo-controlled phase were included in the open-label extension. 
LD: loading dose; MAIC: matching-adjusted indirect comparison; R: randomization; SJC: swollen joint count; TJC: total joint count
SF-36 MCS and PCS scores are reported as chang-
es from baseline; 95% CIs could not be estimated 
in our analysis (Supplementary Methods section).
Results
Principal analysis
Matching baseline characteristics
Significant differences were found between 
patients treated with secukinumab and those 
receiving etanercept before matching, where-
as no significant differences were observed af-
ter matching (Table 1).
ACR response rates
At week 12, placebo-adjusted ACR 20, 50, and 
70 response rates for secukinumab (150 mg or 
300 mg) and for etanercept were similar in the 
principal analysis (Figure 2 and Table 2). At week 
24, ACR 20 and 50 response rates for secukinum-
ab 150 mg and etanercept were not statistically 
different, but ACR 70 response rate was statisti-
cally higher in patients receiving secukinumab 
than in those receiving etanercept (OR (95% 
CI): 4.48 (2.01–9.99), p<0.001). At week 24, ACR 
20, 50, and 70 response rates were statistically 
higher in patients treated with secukinumab 
300 mg than in those receiving etanercept (OR 
(95% CI): ACR 20, 3.28 (1.69–6.38), p<0.001; ACR 
50, 1.90 (1.04–3.50), p=0.038; and ACR 70, 3.56 
(1.51–8.40), p=0.004). This equates to strong evi-
dence for a statistical difference between secuk-
inumab 150 mg and etanercept with respect to 
ACR 70 response rate and between secukinum-
ab 300 mg and etanercept with respect to ACR 
20 response rate at week 24 and increasing ev-
idence for a difference between secukinumab 
300 mg and etanercept with respect to ACR 50 
and 70 response rates.
Changes in SF-36 PCS and MCS scores
As shown in Table 3, mean increase at week 
24 in SF-36 PCS scores from baseline was 
numerically greater for patients receiving 
etanercept than for those receiving secuk-
inumab 150 mg or 300 mg (etanercept, 
9.3; secukinumab 150 mg, 6.58; and secuk-
inumab 300 mg, 9.00). However, both dos-
es of secukinumab were associated with 
numerically higher changes in mean SF-36 
MCS scores from baseline than etanercept 
(etanercept, 2.7; secukinumab 150 mg, 6.03; 
and secukinumab 300 mg, 6.12).
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Figure 2. ACR response rates for secukinumab 150 mg and secukinumab 300 mg compared with etanercept (principal analyses). ACR 20/50/70 
response rates are the absolute mean response rate (NCT00317499) and the predicted mean response rate (FUTURE 2, 3, and 5). An OR <1 favors 
etanercept; an OR >1 favors secukinumab. p values are derived from the ORs and are set at a 5% significance level. The 95% CIs of the OR are shown 
in square brackets. Error bars show 95% CIs on the bar graph. Non-responder imputation was used to match NCT00317499. 
ACR: American College of Rheumatology; ACR 20/50/70: ≥20%/50%/70% improvement according to the ACR response criteria; CI: confidence 
interval; ESS: effective sample size; ETN: etanercept; OR: odds ratio; SEC: secukinumab
Sensitivity analysis
Matching baseline characteristics
After matching, both secukinumab arms were 
well matched with the etanercept arm in the 
sensitivity analysis (Supplementary Table 1).
ACR response rates
Placebo-adjusted ACR 20, 50, and 70 response 
rates were similar for secukinumab (150 mg or 
300 mg) and etanercept at week 12 (Supple-
mentary Figure 1 and Supplementary Table 
2). At week 24, non-placebo-adjusted ACR 50 
response rates were similar for either dose of 
secukinumab and etanercept, but ACR 20 
and 70 response rates were higher in patients 
treated with secukinumab 150 mg than in 
those receiving etanercept (OR (95% CI): ACR 
20, 1.68 (1.06–2.66), p=0.028 and ACR 70, 3.47 
(1.66–7.24), p<0.001). The findings were sim-
ilar for secukinumab 300 mg compared with 
etanercept (OR (95% CI): ACR 20, 2.16 (1.35–
3.47), p=0.001 and ACR 70, 3.70 (1.77–7.75), 
p<0.001). Therefore, these data provide sim-
ilarly strong evidence for secukinumab 150 
mg and secukinumab 300 mg with respect to 
ACR 70 response rates, but stronger evidence 
for the 300 mg dose than for the 150 mg dose 
with respect to ACR 20 response rates.
Changes in SF-36 PCS and MCS scores
As in the principal analysis, mean increase in 
SF-36 PCS scores from baseline was numeri-
cally greater for patients receiving etanercept 
than for those receiving secukinumab 150 mg 
or 300 mg (etanercept, 9.3; secukinumab 150 
mg, 6.22; and secukinumab 300 mg, 7.86; Table 
3). However, both doses of secukinumab were 
associated with numerically higher changes 
in mean SF-36 MCS scores from baseline than 
etanercept (etanercept, 2.7; secukinumab 150 
mg, 5.62; and secukinumab 300 mg, 4.28).
Discussion
The present study used MAIC to examine the 
comparative effectiveness of secukinumab and 
etanercept in biologic-naïve patients with ac-
tive PsA. Our results suggest that secukinumab 
and etanercept have similar short-term effica-
cy with respect to ACR 20, 50, and 70 response 
rates; no differences between the two treat-
Table 2. ACR response rates for secukinumab 150 mg and secukinumab 300 mg compared with etanercept (principal analyses)
                                                        Secukinumab vs. etanercept 25 mg BIW
                                                                  Secukinumab 150 mg                                                 Secukinumab 300 mg
 Week 12 Week 24 Week 12 Week 24
 Placebo-adjusted change Non-placebo-adjusted change Placebo-adjusted change Non-placebo-adjusted 
Outcomes from baseline from baseline from baseline change from baseline
ACR 20 OR (95% CI) 0.57 1.47 0.86 3.28
 (0.25–1.31) (0.85–2.55) (0.36–2.02) (1.69–6.38)
 p=0.186 p=0.173 p=0.722 p<0.001
ACR 50 OR (95% CI) 0.88 1.30 1.21 1.90
 (0.24–3.15) (0.74–2.28) (0.33–4.42) (1.04–3.50)
 p=0.841 p=0.358 p=0.771 p=0.038
ACR 70 OR (95% CI) 0.58 4.48 0.79 3.56
 (0.03–11.39) (2.01–9.99) (0.04–15.68) (1.51–8.40)
 p=0.717 p<0.001 p=0.867 p=0.004
Non-responder imputation used at all time points 
p values were derived from OR values using the Z-statistic. Bold data indicate evidence of a greater response with secukinumab than with etanercept (p≤0.05). Using the updated statistical 
methodology, gray shaded cells indicate "increasing evidence" (p<0.1), and cells with a black outline indicate “strong evidence” (p≤0.001).
ACR: American College of Rheumatology; ACR 20/50/70: ≥20%/50%/70% improvement according to the ACR response criteria; BIW: twice weekly; CI: confidence interval; OR: odds ratio
Table 3. Mean changes from baseline in SF-36 PCS and MCS scores (principal and sensitivity analyses)
  FUTURE 2/3/5 FUTURE 2/3/5 FUTURE 2/3/5 FUTURE 2/3/5 
 NCT00317499 Secukinumab 150 mg Secukinumab 150 mg Secukinumab 300 mg Secukinumab 300 mg 
Outcomes Etanercept 25 mg BIW Principal analysis Sensitivity analysis Principal analysis Sensitivity analysis
SF-36 PCS score, 9.3 6.58 (5.81–7.36) 6.22 (5.50–6.95) 9.00 (8.21–9.79) 7.86 (7.13–8.58) 
mean change from 
baseline (95% CI), 
week 24
SF-36 MCS, score, 2.7 6.03 (5.06–7.00) 5.62 (4.65–6.59) 6.12 (4.91–7.34) 4.28 (3.25–5.31) 
mean change from 
baseline (95% CI), 
week 24
LOCF imputation used in all analyses. Data are shown as mean change from baseline (95% CI)
BIW: twice weekly; CI: confidence interval; LOCF: last observation carried forward; MCS: mental component summary; PCS: physical component summary; SF-36: 36-Item Short-Form Health Survey
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ments were observed at week 12. At week 24, 
advantages were observed with secukinumab 
150 mg with respect to increased ACR 70 re-
sponse rates over etanercept and with secuki-
numab 300 mg with respect to increased ACR 
20, 50, and 70 response rates over etanercept. 
Our findings for ACR 20 and 70 response rates 
are largely supported by the sensitivity anal-
ysis; however, other results are not replicated 
consistently in both scenarios and should be 
treated with caution. This may be because 
our principal analyses used as matching pa-
rameters a comparatively more complete set 
of potential characteristics that may influence 
treatment responses.
Data have been published from FIXTURE 
(NCT01358578), a head-to-head RCT of secuk-
inumab and etanercept in patients with mod-
erate-to-severe psoriasis, showing superiority 
for secukinumab over etanercept (24). A sub-
group analysis of patients with concomitant 
PsA demonstrated greater improvements with 
respect to both skin signs and symptoms and 
physical function, assessed using the Health 
Assessment Questionnaire Disability Index 
(HAQ-DI), for secukinumab than for etanercept 
(25). Our findings are in line with this study, 
particularly as HAQ-DI scores are often used 
to assess physical disability and are part of the 
ACR response criteria.
A recently published network meta-analysis 
(NMA) compared secukinumab with other 
biologic therapies approved for treating PsA; 
however, secukinumab and etanercept were 
compared only with respect to PASI scores. In 
the NMA, secukinumab 150 mg and 300 mg 
demonstrated superiority over etanercept 25 
mg twice weekly and etanercept 50 mg twice 
weekly or once weekly with respect to PASI 50, 
75, or 90 response rates at 12–16 weeks (26).
Our SF-36 analyses examined the impact of 
secukinumab and etanercept on patients’ 
HRQoL, especially well-being and daily func-
tioning. There was evidence of a greater im-
provement in SF-36 PCS scores with etaner-
cept than with secukinumab 150 mg, but 
the improvement with secukinumab 300 
mg was similar to that observed with etaner-
cept at week 24. However, patients in the 
NCT00317499 trial had substantially lower 
SF-36 PCS scores at baseline than those in the 
FUTURE 2, 3, and 5 trials, which may impact 
the comparability of the results. Our findings 
are not in line with the previous head-to-head 
comparison of secukinumab 300 mg and 
etanercept, which indicated comparatively 
higher functional improvement associated 
with secukinumab 300 mg, assessed using the 
HAQ-DI (25). This may be influenced by the dis-
parity in the outcome measures used; HAQ-DI 
measures functional ability only, whereas SF-36 
PCS comprises a more comprehensive and ho-
listic set of items. Improvements from baseline 
in SF-36 MCS scores were greater for patients 
receiving either dose of secukinumab than for 
those receiving etanercept in our study. How-
ever, standard deviations or standard errors 
were not reported in the NCT00317499 trial 
(16), meaning that it was not possible to cal-
culate p values for these comparisons, and the 
results should be interpreted with caution.
Our study has some limitations. First, al-
though efficacy outcomes after week 24 were 
reported in the NCT00317499 trial, times from 
randomization to the start of open-label treat-
ment were different across individuals, and 
therefore the reported results included pa-
tients with different durations of therapy (27). 
Therefore, long-term efficacy outcomes were 
not available for use in our analysis, and no 
valid comparison could be drawn between 
trials. Owing to between-trial differences in 
the placebo arm designs and reporting at 
week 24 and the associated risk of bias, pla-
cebo could not be used for adjustment at this 
time point, and our comparison uses only the 
matched treatment arms as the adjustment 
method. Additionally, the use of stringent cri-
teria to increase the accuracy of the matching 
process resulted in lower, but adequate, ESSs 
for secukinumab in our principal analyses, us-
ing pooled data from FUTURE 2, 3, and 5. An 
alternative to performing MAIC using pooled 
IPD would have been to perform identical 
MAICs based on each IPD population and 
then pool the relative effect estimates with 
standard meta-analysis methods (5); howev-
er, pooling of IPD was considered to be ac-
ceptable because of the similarities in study 
design and protocol. The large differences in 
pre- and post-matching sample sizes demon-
strate the heterogeneity before matching and 
the need for MAIC rather than older methods, 
which compared data from different trials 
without any adjustment.
MAIC also has general limitations. Although 
non-placebo-adjusted comparisons are a le-
gitimate means of comparing treatments us-
ing long-term data, adjustments cannot be 
made for unobserved differences between 
trial populations, variables reported in only 
one study, or certain aspects of study design. 
Furthermore, as in any study, our results are 
most applicable to the study population: the 
NCT00317499 trial population, to which the 
FUTURE 2, 3, and 5 populations were matched. 
Therefore, the results of our MAIC are most 
applicable to patients who are biologic-naïve, 
and cannot be used to draw conclusions 
about the relative efficacy of secukinumab and 
etanercept in patients who have experienced 
biologic therapy failure.
The NICE guidelines recommend quantifi-
cation of the possible extent of any residual 
systematic error resulting from unobserved 
prognostic variables and effect modifiers in 
unanchored comparisons, although this area 
requires further research (8). The guidelines 
propose an out-of-sample method, comparing 
observed and predicted outcomes of the drug 
of interest in a range of different studies in the 
target population. This method was applied in 
our current study using MAICs (with covariate 
adjustments as in our principal analysis) to pre-
dict ACR 20 and 50 response rates for secuk-
inumab in four different PsA trial populations 
(16, 28-30). However, the observed outcomes 
in these trials were found to be very similar, 
so that the between-study standard deviation 
estimated from the meta-analysis was zero. As 
a result, the ratio of the between-studies vari-
ance in predicted to observed outcomes could 
not be calculated. We note that the formula 
suggested by the NICE guidelines requires at 
least some heterogeneity of the trial popula-
tions, which may not be the case if trials use 
very similar inclusion and exclusion criteria.
MAIC analyses cannot replace an appropri-
ately powered, head-to-head RCT, but can 
provide additional insights into comparative 
effectiveness. As well as comparing different 
modes of action, our analysis is also of inter-
est because secukinumab and etanercept are 
the first recommended PsA treatments for 
which head-to-head data were published in a 
subpopulation of patients with psoriasis and 
PsA. Our findings indicate that biologic-naïve 
patients with active PsA have a similar prob-
ability of achieving short-term ACR respons-
es (week 12) with secukinumab and with 
etanercept, but are comparatively more likely 
to achieve ACR responses after 24 weeks of 
treatment with secukinumab. Future direct or 
indirect comparisons, as well as real-world ob-
servations, will be valuable to provide further 
evidence on the relative treatment effects of 
these two therapies.
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Supplementary Methods
Matching-adjusted indirect comparison
Identification of source data by SLR
An SLR with a cut-off of November 2015 was 
used to identify evidence for secukinumab and 
relevant comparators in the treatment of adult 
patients with PsA, with no restriction by dis-
ease severity; eligibility criteria were the same 
as those described previously (1). A Preferred 
Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) flowchart is shown 
in Supplementary Figure 2. A total of 29 trials 
met the eligibility criteria, of which 20 includ-
ed neither secukinumab nor etanercept, and 
7 were excluded for other reasons (Supple-
mentary Table 3). The two trials included in 
our analysis were FUTURE 2 (NCT01752634), a 
placebo-controlled study of secukinumab (2), 
and NCT00317499, a placebo-controlled trial 
of etanercept (3).
In April 2018, IPD from the FUTURE 
3 (NCT01989468) (4) and FUTURE 5 
(NCT02404350) (5) trials became available for 
inclusion in the present study. The FUTURE 2, 
3, and 5 trials were similar with respect to in-
clusion and exclusion criteria, follow-up period, 
intervention, and setting, and included the ap-
proved 150 mg and 300 mg doses of secuki-
numab. This allowed us to pool IPD across the 
three trials, with the aim of increasing the po-
tential ESS following matching, in accordance 
with the recommended methodology (6, 7).
A targeted literature search in PubMed and 
a search of the website (https://clinicaltrials.
gov/) using the keywords “etanercept” and 
“psoriatic arthritis” were performed to identify 
any new published data for etanercept; how-
ever, no relevant data were identified.
Matching and adjusting IPD to published aggre-
gate data
Pooled FUTURE 2, 3, and 5 IPD were weighted 
to match selected patient baseline characteris-
tics using published aggregate data from the 
etanercept arm of NCT00317499 using SAS 
version 9.4 and R version 3.2.1.
The regression results were used to weigh pa-
tients in FUTURE 2, 3, and 5 using the meth-
od of moments (mean only). The method of 
moment was applied using the quasi-Newton 
optimization Broyden–Fletcher–Goldfarb–
Shanno implemented in the R function optim, 
as recommended in the NICE guidelines (6). Af-
ter this matching process, the weighted mean 
baseline characteristics of the pooled FUTURE 
2, 3, and 5 populations matched those report-
ed for NCT00317499, and the sample size of 
the pooled FUTURE 2, 3, and 5 data set was 
reduced to the ESS.
Analyses
Pairwise comparisons
For placebo-adjusted ACR response rate com-
parisons at week 12, ORs for the secukinumab 
arm versus the placebo arm in the matched 
FUTURE 2, 3, and 5 populations were derived 
from a logistic regression model by using gen-
eralized estimating equations (fitted using 
PROC GENMOD in SAS) with robust standard 
errors, following published guidelines (6, 8).
For non-placebo-adjusted comparisons at 
week 24, ORs were calculated as the odds 
of a response in the etanercept arm of 
NCT00317499 by the odds of a response in the 
secukinumab arm of the reweighted pooled 
FUTURE 2, 3, and 5 populations. Standard er-
rors for ORs were estimated based on the infor-
mation provided by a 2×2 contingency table.
Our principal and sensitivity analyses em-
ployed a standard p value threshold of ≤0.05, 
but we also acknowledge the recent American 
Statistical Association guidelines (9, 10) by in-
terpreting our data using a more modern defi-
nition (11, 12). Therefore, we classified p values 
between 0.1 and 0.001 as “increasing evidence” 
and p≤0.001 as “strong evidence” against the 
null hypothesis.
A 95% CI around mean changes from baseline 
in SF-36 MCS and PCS scores for patients in the 
etanercept arm of NCT00317499 could not 
be estimated, as neither standard deviations 
nor standard errors were reported. Therefore, 
full statistical comparisons could not be per-
formed.
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Supplementary Figure 1. PRISMA diagram.
The rules for this SLR were set a priori (as defined in Supplementary Table 3), yielding 29 trials. A second filter was then applied, i.e., studies that 
included either etanercept or secukinumab.
MAIC: matching-adjusted indirect comparison; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; SLR: systematic lit-
erature review
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Supplementary Figure 2. ACR response rates for secukinumab 150 mg and secukinumab 300 mg compared with etanercept: sensitivity analyses.
ACR 20/50/70 responses are the absolute mean response rate (NCT00317499) and the predicted mean response rate (FUTURE 2, 3, and 5). An OR 
<1 favors etanercept; an OR >1 favors secukinumab. Error bars show 95% confidence intervals. The most appropriate imputation methods to match 
NCT00317499 were used.
ACR: American College of Rheumatology; ACR 20/50/70: ≥20/50/70% improvement according to the ACR response criteria; ESS: effective sample 
size; ETN: etanercept, OR: odds ratio; SEC: secukinumab
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Supplementary Table 1. Baseline characteristics before and after matching in the sensitivity analysis
                         NCT00317499 trial                                 FUTURE 2/3/5 (before matching)                                FUTURE 2/3/5 (after matching) 
Baseline ETN 25 mg BIW PBO SEC 150 mg SEC 300 mg PBO SEC 150 mg SEC 300 mg PBO 
characteristics (n=101) (n=104) (n=458) wk 12 (n=461) wk 12 (n=567) (ESS=276) (ESS=253) (ESS=304)
Demographics
Age (years), mean* 47.6 47.3 48.5 (12.3) 48.6 (12.8) 49.4 (12.3) 47.6 (10.0) 47.6 (9.4) 47.3 (9.4)
Weight (kg), median* 88.4 88.4 85.0 82.5 82.3 88.1 88.4 88.6
Female, n (%) 43 (42.6) 57 (54.8) 231 (50.4) 235 (51.0) 308 (54.3) (42.6)† (42.6)† (54.8)†
   p=0.1525 p=0.1261  p=1.000 p=1.000
White, n (%) 91 (90) 95 (91) 397 (86.7) 410 (88.9) 501 (88.4) (90.0)† (90.0)† (90.0)†
   p=0.3505 p=0.7339  p=1.000 p=1.000
Disease characteristics
Methotrexate use 42 (42) 43 (41) 213 (46.5) 227 (49.2) 279 (49.2) (42.0)† (42.0)† (41.0)†
at baseline, n (%)   p=0.3686 p=0.1630  p=1.000 p=1.000
Psoriasis (≥3% BSA) 66 (65.3) 62 (59.6) 251 (54.8) 213 (46.2) 264 (46.6) (65.3)† (65.3)† (59.6)†
n (%)   p=0.0529 p=0.0005  p=1.000 p=1.000
HAQ-DI at baseline, mean* 1.1 1.1 1.2 (0.6) 1.2 (0.6) 1.1 (0.6) 1.1 (0.5) 1.1 (0.5) 1.1 (0.5)
   p=0.1882 p=0.1876  p=1.000 p=1.000
TNFi-naïve, n (%) 101 (100) 104 (100) 312 (68.1) 316 (68.5) 390 (68.7) (100.0)† (100.0)† (100.0)†
   p<0.0001 p<0.0001  p=1.000 p=1.000 
Variables not used for matching
PsA duration (years), 9.0 9.2 7.0 (7.8) 7.3 (8.4) 6.7 (7.4) 6.3 (6.5) 5.6 (5.7) 5.5 (5.6) 
   mean (SD)*
SJC, median* 13.0 12.5 9.0 8.0 8.0 8.0 7.0 8.0
TJC, median 18.0 17.0 16.0 15.0 16.0 15.0 14.0 15.0
CRP levels, median 1.6 1.1 0.5 0.5 0.5 0.4 0.4 0.5
SF-36 PCS, mean 35.8 35.7 36.9 (8.0) 37.7 (8.2) 36.7 (8.4) 38.7 (6.2) 38.9 (6.6) 38.5 (6.9)
SF-36 MCS, mean 50.9 48.4 41.8 (10.8) 44.1 (11.7) 43.7 (11.2) 41.9 (8.7) 44.4 (9.0) 44.9 (8.2)
Bold data indicate the post-matching baseline characteristics in each group
p values are for secukinumab compared with etanercept.
*For continuous baseline characteristics in the NCT00317499 study, either only the median or the mean without SD was reported. Therefore, in both cases, it was not possible to perform a statistical test.
†Integer population (n) values were not available because pooled SEC ESS values were calculated using the  equation.
BIW: twice weekly; BSA: body surface area; CRP: C-reactive protein; ESS: effective sample size; ETN: etanercept; HAQ-DI: Health Assessment Questionnaire Disability Index; MCS: mental component 
summary; PBO: placebo; PCS: physical component summary; PsA: psoriatic arthritis; SD: standard deviation; SEC: secukinumab; SF-36: 36-Item Short-Form Health Survey; SJC: swollen joint count; 
TJC: tender joint count; TNFi: tumor necrosis factor inhibitor
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Supplementary Table 2. ACR response rates for secukinumab 150 mg and secukinumab 300 mg compared with etanercept (sensitivity analyses)
                                                        Secukinumab vs. etanercept 25 mg BIW
                                                                  Secukinumab 150 mg                                                 Secukinumab 300 mg
 Week 12 Week 24 Week 12 Week 24
 Placebo-adjusted change Non-placebo-adjusted change Placebo-adjusted change Non-placebo-adjusted 
Outcomes from baseline from baseline from baseline change from baseline
ACR 20 OR (95% CI) 0.44 1.68 0.65 2.16
 (0.21–0.93) (1.06–2.66) (0.31–1.38) (1.35–3.47)
 p=0.032 p=0.028 p=0.264 p=0.001
ACR 50 OR (95% CI) 0.43 1.22 0.63 1.45
 (0.13–1.42) (0.76–1.96) (0.19–2.09) (0.90–2.32)
 p=0.168 p=0.401 p=0.452 p=0.128
ACR 70 OR (95% CI) 0.23 3.47 0.30 3.70
 (0.01–4.29) (1.66–7.24) (0.02–5.75) (1.77–7.75)
 p=0.322 p<0.001 p=0.426 p<0.001
Non-responder imputation used at all time points. p values were derived from OR values using the Z-statistic. Bold data indicate evidence of a greater response with secukinumab than with etanercept 
(p≤0.05). Using the alternative interpretation of p values, gray shaded cells indicate “increasing” evidence (p<0.1), and cells with a black outline indicates “strong evidence” (p≤0.001).
ACR: American College of Rheumatology; ACR 20/50/70: ≥20%/50%/70% improvement according to the ACR response criteria; BIW: twice weekly; CI: confidence interval; OR: odds ratio
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Supplementary Table 3. Trials identified in the SLR and the reasons for their inclusion/exclusion in this MAIC
    Primary study Secondary Study included in 
Trial acronym Intervention Comparator Population reference references MAIC analysis?
CLEAR Secukinumab 300 Ustekinumab 45 mg CLEAR included 676 Gottlieb (13) None No—these trials were 
(subanalysis) mg (s.c.); weeks 0, 1, 2, for individuals ≤100 kg patients with   designed to assess 
 and 3 and Q4W and 90 mg for moderate-to-severe   dermatologic endpoints 
 from week 4 individuals >100 kg psoriasis whose disease   in psoriasis and 
  (s.c.); weeks 0, 4, and was inadequately   consequently did not 
  Q12W from week 16 controlled by   collect data on 
   topical treatment,   rheumatology disease 
   phototherapy, and/or   characteristics at 
   previous systemic   baseline or assess 
   therapy. 123 had   ACR response rates. 
   concomitant PsA   This meant that matching  
      and comparison of outcomes 
      in our analysis would not have 
      been possible. Furthermore, 
      all patients had moderate-to 
      severe psoriasis, which 
      resulted in a discrepancy in 
      baseline PASI scores between 
      the population in this trial and 
      the patients in other trials 
      identified in the SLR
ERASURE Secukinumab 300 Placebo ERASURE included Gottlieb (14) Blauvelt (16) 
(subanalysis) mg or 150 mg give at  patients with Gottlieb (15) Gottlieb (17) 
 weeks 0, 1, 2, 3, and  moderate-to-severe  Philipp (18) 
 4 and Q4W thereafter  psoriasis whose disease 
 through week 48  was poorly controlled 
   by topical treatment, 
   phototherapy, and/o 
    previous systemic 
   therapy. 171 had 
   concomitant PsA
FIXTURE Secukinumab 300 Placebo FIXTURE included Gottlieb (15) Gottlieb (19) 
(subanalysis)  mg or 150 mg  patients with  Philipp (18) 
 QW for 4 weeks  moderate-to-severe  Sigurgeirsson (20) 
   psoriasis whose 
   disease was poorly 
   controlled by topical 
   treatment, phototherapy, 
   and/or previous 
   systemic therapy. 
   196 had concomitant PsA
FUTURE 1 Secukinumab 10 Placebo: i.v. at 606 patients with Mease (21) Gottlieb (22) No—intravenous 
 mg/kg i.v. at weeks weeks 0, 2, and 4 PsA and inadequate  Mease (23) loading for 
 0, 2, and 4 followed and s.c.Q4W thereafter response or intolerance  Mease (24) secukinumab 
 by 150 mg or  to NSAIDs  Mease (25) 
 75 mg s.c. Q4W    Strand (26) 
 thereafter       van der Heijde (27)
FUTURE 2 Secukinumab 300 mg Placebo 298 patients with McInnes (2) Gottlieb (28) Yes 
 or 150 mg QW  active PsA despite  Gottlieb (29) 
 from baseline to  treatment with NSAIDs,  Kavanaugh (30) 
 week 4 and then Q4W  DMARDs, or TNFis  McInnes (31) 
     Mease (32) 
     Rahman (33)
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Supplementary Table 3. Trials identified in the SLR and the reasons for their inclusion/exclusion in this MAIC (Continued)
    Primary study Secondary Study included in 
Trial acronym Intervention Comparator Population reference references MAIC analysis?
McInnes Secukinumab 10 Placebo 42 patients with McInnes (34) McInnes (35) No—intravenous 
(2014) mg/kg i.v. at  active PsA  McInnes (36) loading for secukinumab 
 weeks 0 and 3   
Mease (2000)  Etanercept 25 mg BIW Placebo 60 patients Mease (37) None No—the study 
   with active PsA and    duration was only 
   nadequate response   12 weeks, and this 
   to NSAIDs   trial was a proof-of-concept 
      study rather than a 
      phase 3 trial
NCT00317499 Etanercept 25 mg Placebo 205 patients with Mease (3) Atteno (38) Yes 
(2004) BIW for 24 weeks  active PsA and  Mease (39) 
   inadequate response  Mease (40) 
   to NSAIDs 
PRESTA Etanercept Etanercept 748 patients with Sterry (41) Gniadecki (42) No—all patients had 
 50 mg BIW 50 mg QW psoriasis and  Griffiths (43) moderate-to-severe 
   concomitant PsA  Helliwell (44) psoriasis, which resulted 
     Prinz (45) in a discrepancy in 
      baseline PASI scores between 
      the population in this trial 
      and the patients in other trials 
      identified in the SLR. 
      Restriction of our analysis 
      only to patients in this 
      subgroup to account for this 
      discrepancy would have 
      limited the available data set, 
      and consequently trials 
      restricted by psoriasis disease 
      severity were excluded
Gray shaded rows indicate trials that were included in our analysis
ACR: American College of Rheumatology; BIW: twice weekly; DMARD: disease-modifying anti-rheumatic drug; i.v., intravenously; MAIC: matching-adjusted indirect comparison; NSAID: non-steroidal 
anti-inflammatory drug; PASI: Psoriasis Area and Severity Index; PsA: psoriatic arthritis; Q4W: every 4 weeks; Q12W: every 12 weeks; QW: once weekly; s.c.: subcutaneously; SLR: systematic literature 
review; TNFi: tumor necrosis factor inhibitor 
